Virscio Inc, formerly RxGen, Inc., operates as a translational research company. It focuses on the development and application of clinically relevant models of human disease, physiology, and drug metabolism and pharmacokinetics designed to accelerate the evaluation, selection, and development of candidate therapeutics and drug delivery technologies. These models and services focus on central nervous system, ophthalmic, and metabolic disorders. RxGen has helped academic organizations, venture-backed startups, and pharmaceutical and biotechnology companies.
